A new series of copper(II) complexes of tri substituted 1,3,5 triazine based ligand N2-Phenyl-N4,N6-di(thiazol-2-yl)-1,3,5-triazine-2,4,6-triamine have been synthesized. The structural features of the ligand and its metal complexes have been characterized by micro analytical data, magnetic susceptibility measurements, molar conductance, IR, UV-Visible, 1HNMR, Mass and EPR spectral techniques. The non-electrolytic behaviour of the complexes was confirmed from their conductance data. The electrochemical behaviour of the complexes has been studied by cyclic voltammetry. The free ligand and its metal complexes have been screened for their in vitro biological activity against bacteria Staphylococcus aureus and Escherichia coli and the fungi Candida albicans and Aspergillus niger by well diffusion method.The free ligand and the Cu(II) complexes have been screened for in vivo anticonvulsant activity by maximal electroshock method and have shown significant activity. Carrageenan induced rat paw edema is the most widely used primary test to screen inflammation which measures the ability of the compounds to reduce local edema induced in the rat paw by carrageenan. The ligand and Cu[(PDTTA)(ac)2] areidentified as a new lead structure, demonstrated anti-inflammatory properties in preliminary studies in mice. Molecular docking study was conducted to study the molecular mechanism of anti-inflammatory activity. Cu[(PDTTA)(ac)2] is found to be potent inhibitor of PDE4 enzyme which is involved in the inflammation process.